Potential Chagas vaccine candidate shows unprecedented efficacy

March 26, 2013, University of Texas Medical Branch at Galveston

Scientists are getting closer to a Chagas disease vaccine, something many believed impossible only 10 years ago. Research from the Sealy Center for Vaccine Development at the University of Texas Medical Branch at Galveston has resulted in a safe vaccine candidate that is simple to produce and shows a greater than 90 percent protection rate against chronic infection in mice.

In a paper published online in PLOS ONE, the researchers describe how they identified and tested potential Trypanosoma cruzi (also known as T. cruzi or Chagas disease) antigen candidates and delivery models to establish the safety and efficacy of a formulation known asTcVac3. This potential vaccine could halt the irreversible heart and organ damage that afflicts approximately 30 percent of those infected with Chagas.

"This signals a – unprecedented for a common with no cure for chronic sufferers," said lead author Nisha Garg, PhD, professor of microbiology, immunology and pathology at UTMB. "If this vaccine proves practical, it could be approved in as few as five years for use in canines, which are reservoir hosts of the disease. As many as 20 percent of dogs may be infected in Texas alone, developing the same as humans but mistaken by vets for heartworm."

The study also provides further evidence that a human Chagas vaccine is possible, a topic of debate among some who still believe that Chagas heart disease is the result of an autoimmune disorder, she added.

T. cruzi, transmitted by the triatomine insect, or "," is prevalent in almost all Latin American countries and is becoming more common in the U.S. The estimates that approximately 10 million people – mostly children – are infected worldwide. Approximately 13,000 die each year from the complications of Chagas-induced heart disease – a result of the chronic infection Garg and her team aim to vaccinate against. It is estimated that the global economic burden of Chagas is about $7 billion a year.

TcVac3: The Path of Discovery

TcVac3 is the result of rigorous computational/bioinformatics analysis and screening of the T. cruzi genome for potential candidate antigens over several years by Garg and her team. These analyses led the researchers to three potential antigens (TcG1, TcG2 and TcG4) for further investigation.

Next, they began testing these antigens and potential vaccine delivery models – how the components are arranged in the actual vaccine – to determine the best approaches.

Early experiments proved that delivery of the candidate antigens by a DNA-prime/protein boost approach, along with co-delivery of IL-12 and GM-CSF cytokine adjuvants meant to enhance the immune response, was effective in generating antibody and T cell responses capable of providing more than 90 percent control of acute infection and parasite burden in infected mice.

Recognizing, however, that this vaccine delivery model was quite complex, the scientists sought to simplify the vaccine using a DNA-prime/Modified Vaccinia Ankara (MVA)-boost approach – a delivery model that offers many advantages: it can accommodate multiple foreign genes in its genome; may be administered by a variety of routes; has an excellent safety record; and has been shown to generate immune responses to a variety of foreign antigens. MVA itself can act as an adjuvant since it provides a signal to the innate immune system and can boost T cells.

Based on preliminarystudies by the researchers that showed this delivery model to be potent, the scientists next tested the protective efficacy of TcVac3, constituted of just the TcG2 and TcG4 candidates and lacking the adjuvants, delivered by the DNA/MVA approach.

With two doses of the vaccine, the mice with TcVac3-induced antibodies exhibited 92 to 96 percent protection against chronic infection. They found that the DNA/MVA approach increased the vaccine efficacy enough to omit one of the antigens and the adjuvants, making it a much simpler but still highly effective vaccine.

"Because Chagas is most prevalent in developing countries, it is essential that a potential vaccine be inexpensive to develop and easy to deliver," said Garg. "TcVac3 accomplishes this goal, making it not just an effective candidate, but an ideal one."

Future research will determine if the vaccine composition can be simplified even further. In addition, the scientists are already conducting related trials in canines. Garg and her team are also working on pre-clinical trials of human patient samples, testing for immune response in patients that are already infected but not showing signs of chronic disease. Results of both studies are anticipated later this year.

Explore further: UGA animal vaccine may slow deadly spread of Chagas disease

Related Stories

UGA animal vaccine may slow deadly spread of Chagas disease

February 16, 2012
Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global ...

New study highlights Chagas disease as a growing health and socio-economic challenge

February 7, 2013
Today, The Lancet Infectious Diseases published a new report that examines the global economic burden of Chagas disease. In the first study of its kind, researchers measured the health and economic impact of Chagas disease ...

Research describes advantages of new vaccine adjuvant

December 12, 2011
New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest ...

HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates

March 7, 2012
An Atlanta research collaboration may be one step closer to finding a vaccine that will provide long-lasting protection against repeated exposures to human immunodeficiency virus (HIV). Scientists at Emory University and ...

Cure in sight for kissing bug's bite

February 14, 2013
Chagas disease, a deadly tropical infection caused by the protozoan parasite Trypanosoma cruzi and transmitted by biting insects called "kissing bugs," has begun to spread around the world, including the U.S. Yet current ...

Recommended for you

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.